Literature DB >> 17909904

Activin a causes cancer cell aggressiveness in esophageal squamous cell carcinoma cells.

Keiji Yoshinaga1, Keishi Yamashita, Koshi Mimori, Fumiaki Tanaka, Hiroshi Inoue, Masaki Mori.   

Abstract

BACKGROUND: Expression of activin A is associated with lymph node metastasis and clinical stage in esophageal cancer.
METHODS: To clarify the aggressive behavior of tumors with high activin A expression, we used the beta subunit of activin A to establish stable activin betaA (Act-betaA)-transfected carcinoma cells in two human esophageal carcinoma cell lines, KYSE110 and KYSE140. The biological behavior of these cells was compared with that in mock-transfected cells from the same cell lines. We focused our attention on cell growth and tumorigenesis, and proliferation and apoptosis.
RESULTS: Both Act-betaA-transfected carcinoma cell lines showed a higher growth rate than the mock-transfected carcinoma cells. In an in vitro invasion assay and a xenograft analysis, the Act-betaA-transfected carcinoma cells showed far higher proliferation in vitro and a higher potency for tumorigenesis in vivo, respectively. Moreover, in an analysis of apoptosis via Fas stimulation, the Act-betaA-transfected carcinoma cells showed a higher tolerance to apoptosis compared with the mock-transfected carcinoma cells. Moreover, anti-activin-neutralizing antibody-treated squamous cell cancer cell lines inhibited their migration.
CONCLUSIONS: Collectively, these data indicate that continuous high expression of activin A in esophageal carcinoma cells is not related to tumor suppression, but rather to tumor progression in vitro and in vivo. The inhibition of activin might be one of the methods to attenuate tumor aggressiveness.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17909904     DOI: 10.1245/s10434-007-9631-1

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  23 in total

1.  Loss of ACVRIB leads to increased squamous cell carcinoma aggressiveness through alterations in cell-cell and cell-matrix adhesion proteins.

Authors:  Holli A Loomans; Shanna A Arnold; Kate Hebron; Chase J Taylor; Andries Zijlstra; Claudia D Andl
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

2.  Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma.

Authors:  Christopher W Seder; Wibisono Hartojo; Lin Lin; Amy L Silvers; Zhuwen Wang; Dafydd G Thomas; Thomas J Giordano; Guoan Chen; Andrew C Chang; Mark B Orringer; David G Beer
Journal:  Neoplasia       Date:  2009-04       Impact factor: 5.715

3.  Activin A expression in esophageal carcinoma and its association with tumor aggressiveness and differentiation.

Authors:  Zhenhua Wang; Ning Zhang; Ruifeng Song; Ruitai Fan; Liuqin Yang; Liping Wu
Journal:  Oncol Lett       Date:  2015-05-20       Impact factor: 2.967

4.  Activin upregulation by NF-κB is required to maintain mesenchymal features of cancer stem-like cells in non-small cell lung cancer.

Authors:  J Jacob Wamsley; Manish Kumar; David F Allison; Sheena H Clift; Caitlyn M Holzknecht; Szymon J Szymura; Stephen A Hoang; Xiaojiang Xu; Christopher A Moskaluk; David R Jones; Stefan Bekiranov; Marty W Mayo
Journal:  Cancer Res       Date:  2014-11-28       Impact factor: 12.701

5.  Characterization of apoptosis and proliferation in esophageal carcinoma EC109 cells following siRNA-induced down-regulation of TRAF6.

Authors:  Tianzhong Ma; Ning Wang; Zhongjing Su; Ling Chen; Ningxia Zhu; Changhui Ma; Xiancai Chen; Haibin Chen
Journal:  Mol Cell Biochem       Date:  2011-02-11       Impact factor: 3.396

6.  TRAF6 promoted the tumorigenicity of esophageal squamous cell carcinoma.

Authors:  Feng Yao; Qingqi Han; Chenxi Zhong; Heng Zhao
Journal:  Tumour Biol       Date:  2013-06-22

7.  Clinical Significance of INHBA Gene Expression in Patients with Gastric Cancer who Receive Curative Resection Followed by Adjuvant S-1 Chemotherapy.

Authors:  Yusuke Katayama; Takashi Oshima; Kentaro Sakamaki; Toru Aoyama; Tsutomu Sato; Katsuhiko Masudo; Manabu Shiozawa; Takaki Yoshikawa; Yasushi Rino; Toshio Imada; Munetaka Masuda
Journal:  In Vivo       Date:  2017 Jul-Aug       Impact factor: 2.155

8.  Tumor transcriptome sequencing reveals allelic expression imbalances associated with copy number alterations.

Authors:  Brian B Tuch; Rebecca R Laborde; Xing Xu; Jian Gu; Christina B Chung; Cinna K Monighetti; Sarah J Stanley; Kerry D Olsen; Jan L Kasperbauer; Eric J Moore; Adam J Broomer; Ruoying Tan; Pius M Brzoska; Matthew W Muller; Asim S Siddiqui; Yan W Asmann; Yongming Sun; Scott Kuersten; Melissa A Barker; Francisco M De La Vega; David I Smith
Journal:  PLoS One       Date:  2010-02-19       Impact factor: 3.240

Review 9.  Activins and activin antagonists in hepatocellular carcinoma.

Authors:  Alev Deli; Emanuel Kreidl; Stefan Santifaller; Barbara Trotter; Katja Seir; Walter Berger; Rolf Schulte-Hermann; Chantal Rodgarkia-Dara; Michael Grusch
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

10.  S-100B concentrations predict disease-free survival in stage III melanoma patients.

Authors:  S Kruijff; E Bastiaannet; A C Muller Kobold; R J van Ginkel; A J H Suurmeijer; H J Hoekstra
Journal:  Ann Surg Oncol       Date:  2009-12       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.